Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2354 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
NMDAR/HDAC-IN-1
<p>Compound 9d is a dual NMDAR and HDAC inhibitor with high NMDAR affinity (Ki=0.59 μM) and inhibits HDAC1-3,6,8; crosses the blood-brain barrier.</p>Fórmula:C22H28N2O3Cor e Forma:SolidPeso molecular:368.47CRV431
CAS:CRV431 is a novel Pan-Cyclophilin Inhibitor, potently inhibiting all cyclophilin isoforms tested - A, B, D, and G (IC50 values ranged from 1-7 nM).Fórmula:C67H122N12O13Cor e Forma:SolidPeso molecular:1303.76DCHC
CAS:<p>DCHC is an activator of SIRT1, but it does not induce SIRT1 expression. This compound can be utilized in studies related to mitochondrial damage.</p>Fórmula:C15H8Cl2O3Cor e Forma:SolidPeso molecular:307.128HDAC-IN-32
HDAC-IN-32, potent inhibitor: IC50—HDAC1 (5.2 nM), HDAC2 (11 nM), HDAC6 (28 nM). Effective anti-tumor and immunity-boosting traits.Fórmula:C20H23N3O3Cor e Forma:SolidPeso molecular:353.41Sapintoxin D
CAS:Sapintoxin D is a fluorescent phorbol ester and selective activator of protein kinase C.Fórmula:C30H37NO8Cor e Forma:SolidPeso molecular:539.62HIF-1/2α-IN-1
HIF-1/2α-IN-1, an orally active compound, functions as an inhibitor of HIF-2α.Fórmula:C17H16N6O4Cor e Forma:SolidPeso molecular:368.35Enzomenib
CAS:<p>Enzomenib (DSP5336), a menin protein inhibitor encoded by the multiple endocrine neoplasia (MEN) gene, blocks the interaction between menin protein and mixed lineage leukemia (MLL) fusion proteins. This compound is utilized in researching hematological malignancies.</p>Fórmula:C33H43FN6O3Cor e Forma:SolidPeso molecular:590.73EZH2-IN-12
EZH2-IN-12 (Compound 5) is a potent inhibitor of EZH2, which has potential for studies of CNS malignancies.Fórmula:C23H23Cl2N3O3Cor e Forma:SolidPeso molecular:460.35PF-06726304 acetate
CAS:<p>PF-06726304 acetate is a selective inhibitor of EZH2, with robust antitumor growth activity.</p>Fórmula:C24H25Cl2N3O5Pureza:98%Cor e Forma:SolidPeso molecular:506.38JAK1-IN-9
CAS:JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.Fórmula:C16H13IN6Cor e Forma:SolidPeso molecular:416.22MI-1481
CAS:MI-1481: potent MML1 inhibitor, IC50 3.6 nM; disrupts menin-MLL1, active in MLL leukemia.Fórmula:C29H30F3N7O2SPureza:98%Cor e Forma:SolidPeso molecular:597.65KDOAM-25 citrate
CAS:KDOAM-25 citrate inhibits KDM5A/B/C/D (IC50: 71, 19, 69, 69 nM); boosts H3K4 methylation, hinders MM1S cell growth. [1]Fórmula:C21H33N5O9Pureza:98%Cor e Forma:SolidPeso molecular:499.51MMSET-IN-1
CAS:MMSET-IN-1 is an inhibitor of multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) .Fórmula:C18H29N7O5Pureza:98%Cor e Forma:SolidPeso molecular:423.47HDAC6-IN-13
<p>HDAC6-IN-13: potent, selective HDAC6 inhibitor; oral; IC50=0.019μM; targets HDAC1/2/3; crosses blood-brain barrier; anti-inflammatory.</p>Fórmula:C23H22N4OCor e Forma:SolidPeso molecular:370.45PARP7-IN-12
CAS:PARP7-IN-12, a potent inhibitor targeting PARP7, exhibits an IC50 of 7.836 nM. This compound is applicable in cancer research.Fórmula:C23H27ClF3N5O5Cor e Forma:SolidPeso molecular:545.94Equisetin
CAS:Equisetin: a QSI from Fusarium equiseti, curbs P. aeruginosa virulence, fights Gram-positive bacteria & HIV-1 integrase; not antibacterial to Gram-negative.Fórmula:C22H31NO4Pureza:98%Cor e Forma:SolidPeso molecular:373.49BET-IN-1
BET-IN-1 is a potent inhibitor of BET, exhibiting good brain permeability and a reasonable metabolic stability.Fórmula:C23H24ClFN4O3SCor e Forma:SolidPeso molecular:490.98KDOAM-25 trihydrochloride
<p>KDOAM-25 trihydrochloride selectively inhibits KDM5 enzymes, boosts H3K4 methylation, and suppresses MM1S cell growth.</p>Fórmula:C15H28Cl3N5O2Cor e Forma:SolidPeso molecular:416.77LSD1-IN-19
LSD1-IN-19 is a potent, selective LSD1 inhibitor with Ki of 0.108 μM and 72h IC50 values of 0.17-0.40 μM.Fórmula:C33H42N6O2Cor e Forma:SolidPeso molecular:554.73LSD1/2-IN-4
LSD1/2-IN-4, a PCPA derivative, inhibits LSD1 (Ki 0.11 μM) & LSD2 (Ki 130 μM), potentially useful in T-cell leukemia research.Fórmula:C9H8BrF2NCor e Forma:SolidPeso molecular:248.07AZ-3
CAS:AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Fórmula:C20H28FN7Pureza:98%Cor e Forma:SolidPeso molecular:385.48SGC6870N
CAS:<p>SGC6870N is inactive against PRMT6 and can be used as a negative control. It is the inactive enantiomer of SGC6870.</p>Fórmula:C23H21BrN2O2SPeso molecular:469.39HuR degrader 2
CAS:<p>HuRdegrader 2 (Compound 3) is a molecular glue that targets and degrades the RNA-binding protein Hu antigen R (HuR), achieving 30% degradation at 0.1 μM. It inhibits the proliferation of Colo-205 cancer cells with an IC50 of ≤200 nM. HuRdegrader 2 also shows high affinity for cereblon with an HTRF ratio < 0.02.</p>Fórmula:C20H15N3O3Peso molecular:345.35HDAC-IN-27
<p>HDAC-IN-27 is a potent and orally active inhibitor of HDAC Class I (0.43 nM - 3.01 nM for HDAC1-3).</p>Fórmula:C20H22N4O2Cor e Forma:SolidPeso molecular:350.41B026
CAS:<p>B026: Oral p300/CBP HAT inhibitor, IC50: p300 1.8 nM, CBP 9.5 nM; targets AR+ prostate cancer cells.</p>Fórmula:C27H23F4N5O4Cor e Forma:SolidPeso molecular:557.5Octyl-α-hydroxyglutarate
CAS:<p>Octyl-α-hydroxyglutarate (octyl-2-HG) enhances histone methylation and boosts the viability of LMP1-negative nasopharyngeal carcinoma (NPC) cells.</p>Fórmula:C13H24O5Peso molecular:260.33MS8815
CAS:<p>MS8815 is a selective EZH2 PROTAC degrader with IC50 of 8.6 nM, used in triple-negative breast cancer research.</p>Fórmula:C65H87N9O8SCor e Forma:SolidPeso molecular:1154.51NPC26
CAS:<p>NPC26 is a small molecule that disrupts mitochondrial function and exhibits antitumor activity. It shows significant antiproliferative and cytotoxic effects on CRC cell lines (HCT-116, DLD-1, and HT-29). NPC26 induces mitochondrial permeability transition pore (mPTP) opening, generates reactive oxygen species (ROS), and triggers cell death. Additionally, NPC26 kills CRC cells by activating the AMP-activated protein kinase (AMPK) signaling pathway.</p>Fórmula:C19H23N3O5S2Cor e Forma:SolidPeso molecular:437.533BRD4/NAMPT-IN-1
CAS:BRD4/NAMPT-IN-1 (Compound A2) exhibits strong inhibitory effects on NAMPT and BRD4, with IC50 values of 35 nM (NAMPT) and 58 nM (BRD4). This compound significantly suppresses the growth and migration of liver cancer cells while promoting apoptosis. Additionally, BRD4/NAMPT-IN-1 demonstrates potent anticancer activity in HCCLM3 xenograft mouse models without noticeable toxicity.Fórmula:C30H30ClN7O2SPeso molecular:588.12BRD4 Inhibitor-32
CAS:<p>BRD4 Inhibitor-32 (example 15), a BRD4 inhibitor, is applicable in research pertaining to both acute and chronic kidney disease [1].</p>Fórmula:C26H25N3O3Cor e Forma:SolidPeso molecular:427.5AR/BET protein degrader-1
CAS:AR/BET protein degrader-1 (Compound 149) is a dual-targeting protein degrader of Androgen Receptor and BET (bromodomain and extra-terminal domain), suitable for cancer research.Fórmula:C43H44N6O5Peso molecular:724.85LSD1-IN-18
<p>LSD1-IN-18 inhibits LSD1 (Ki: 0.156 μM, KD: 0.075 μM), blocking THP-1 and MDA-MB-231 cell growth (IC50: 0.16, 0.21 μM).</p>Fórmula:C31H40N6O2Cor e Forma:SolidPeso molecular:528.69PAD2-IN-1 hydrochloride
PAD2-IN-1 hydrochloride: potent, selective PAD2 inhibitor; 95x less on PAD4, 79x less on PAD3; benzimidazole derivative.Fórmula:C25H30ClFN6O3Cor e Forma:SolidPeso molecular:517JAK3-IN-7
CAS:<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Fórmula:C17H20N6OPureza:98.81%Cor e Forma:SolidPeso molecular:324.38BET-IN-8
BET-IN-8 (Compound 27) is a potent inhibitor of BET (Ki: 0.83 μM, Kd: 0.571 μM), which ameliorates LPS-induced sepsis in vivo.BET-IN-8 has shown potential inFórmula:C22H21N3O4SCor e Forma:SolidPeso molecular:423.48Triciferol
CAS:<p>Triciferol is a VDR agonist and HDAC antagonist with 1,25D-like potency, affecting gene targets and tubulin, and shows anti-cancer effects in vitro. IC50=87nM.</p>Fórmula:C26H39NO4Cor e Forma:SolidPeso molecular:429.591HDAC6-IN-9
CAS:HDAC6-IN-9 is a γ-secretase modulator that can significantly reduce the level of Aβ42 in mouse brain and can be used to study neurological diseases.Fórmula:C19H16N2O3Pureza:98.84%Cor e Forma:SolidPeso molecular:320.34O-Desmethyl Midostaurin
CAS:O-Desmethyl Midostaurin is the active Midostaurin metabolite via cytochrome P450 liver enzyme metabolism.Fórmula:C34H28N4O4Pureza:98%Cor e Forma:SolidPeso molecular:556.61DS17701585
DS17701585: Oral EP300/CBP inhibitor; potent on CBP, EP300, H3K27, & SOX2; useful for cancer research.Fórmula:C24H26N4O5SCor e Forma:SolidPeso molecular:482.55BRD4-BD1/2-IN-2
CAS:BRD4-BD1/2-IN-2 inhibits BRD4 BD1/BD2 with IC50 <300 nM/<0.5 nM (WO2021233371A1).Fórmula:C30H33N5O4Cor e Forma:SolidPeso molecular:527.61HDAC2-IN-1
HDAC2-IN-1 is an oral HDAC2 inhibitor (IC50: 0.5 μM), crosses the blood-brain barrier, and inhibits HDAC1 and HDAC8.Fórmula:C22H23ClN4OSCor e Forma:SolidPeso molecular:426.96CBP/p300-IN-16
<p>CBP/p300-IN-16 (compound 1) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.61 μM) and LK2 H3K27 (IC50: 2.24 μM).</p>Fórmula:C26H31N3O4Cor e Forma:SolidPeso molecular:449.54HDAC-IN-33
HDAC-IN-33 inhibits HDAC1/2/6 (IC50: 24/46/47 nM), exhibits potent antitumor activity in vitro and in vivo, and activates antitumor immunity.Fórmula:C21H25N3O3Cor e Forma:SolidPeso molecular:367.44PARP10/15-IN-1
PARP10/15-IN-1 (compound 8l) is a dual PARP10 and PARP15 inhibitor with IC50s of 160 nM and 370 nM, respectively. It can be used in cancer research[1].Fórmula:C13H10N2O3SCor e Forma:SolidPeso molecular:274.3EBET-590
CAS:<p>EBET-590 is a BET inhibitor utilized in cancer research.</p>Fórmula:C26H26N4O3Peso molecular:442.51RK-582
CAS:RK-582: oral spiroindolinone tankyrase inhibitor, halts colon cancer growth in COLO-320DM mouse model.Fórmula:C27H35FN6O3Cor e Forma:SolidPeso molecular:510.6EN884
CAS:EN884 is a BRD4 degrader that functions through an SKP1 and proteasome-dependent degradation pathway. It is utilized in the synthesis of proteolysis-targeting chimeras (PROTAC).Fórmula:C14H18N2OPeso molecular:230.31HDAC/HSP90-IN-4
HDAC/HSP90-IN-4 inhibits HDAC (20 IC50=194nM, 26 IC50=360nM) & HSP90α (20 IC50=153nM, 26 IC50=77nM), affects cancer cell survival and invasion.Fórmula:C20H23N3O6Cor e Forma:SolidPeso molecular:401.15869SMARCA2-IN-6
CAS:<p>SMARCA2-IN-6 is a potent inhibitor of SMARCA2 (also known as BRM), exhibiting an IC50 of less than 5 nM against both SMARCA2 and SMARCA4. Additionally, this compound suppresses the expression of the KRT80 gene in H1299 cells with an IC50 of 26 nM and inhibits the proliferation of SKMEL5 cells carrying a BRG1 mutation with an IC50 value of 13 nM.</p>Fórmula:C10H8ClF2N5OSCor e Forma:SolidPeso molecular:319.72AZ0108
CAS:<p>AZ0108, an oral PARP1,2,6 inhibitor, selectively blocks centrosome clustering, is viable for in vivo studies, and doesn't inhibit PARP3/TNKS1.</p>Fórmula:C24H20F4N6O2Cor e Forma:SolidPeso molecular:500.45LSD1/2-IN-3
LSD1/2-IN-3 selectively inhibits LSD1 (Ki 11 nM) over LSD2 (Ki 7 μM), and hinders tumor stem cell proliferation.Fórmula:C9H8BrF2NCor e Forma:SolidPeso molecular:248.07AZ13824374
AZ13824374: potent, selective ATAD2 inhibitor; anti-proliferative in breast cancer; pIC50: FRET 8.2, NanoBRET 6.2.Fórmula:C30H39FN8O2Cor e Forma:SolidPeso molecular:562.68CFT8634
CAS:CFT8634 degrades BRD9, for synovial sarcoma and SMARCB1 tumor research, from patent WO2021178920A1.Fórmula:C37H45F3N6O5Cor e Forma:SolidPeso molecular:710.79LSD1-IN-17
<p>LSD1-IN-17, a potent LSD1/CoREST/MAO inhibitor, IC50: 0.005/0.028/0.820 μM; hinders LNCaP prostate cancer cell growth, IC50: 17.2 μM.</p>Fórmula:C20H18N2OSCor e Forma:SolidPeso molecular:334.43Tyk2-IN-15
CAS:<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Fórmula:C21H25F2N7OCor e Forma:SolidPeso molecular:429.47PAD-IN-2
CAS:<p>PAD-IN-2, potent PAD4 inhibitor, IC50 <1 μM; targets autoimmune/cancer disorders.</p>Fórmula:C27H28ClN5O2Cor e Forma:SolidPeso molecular:490BRD4 D1-IN-2
<p>BRD4 D1-IN-2 (compound 26), a BRD4 D1 inhibitor, IC50 <0.092 μM, 15 nM affinity, >500x selectivity over BRD2 D1/BRD4 D2.</p>Fórmula:C33H39F3N6OCor e Forma:SolidPeso molecular:592.7LSD1-IN-13 hydrochloride
CAS:<p>LSD1-IN-13 hydrochloride (7e) is an oral LSD1 inhibitor (IC50: 24.43 nM), promoting differentiation in AML cell lines.</p>Fórmula:C23H30ClN3O2SCor e Forma:SolidPeso molecular:448.02ROPA
CAS:ROPA, a potent PKCalpha and PKCgamma activator, promotes tumor growth through PKC-activation.Fórmula:C28H32O6Pureza:98%Cor e Forma:SolidPeso molecular:464.55PRMT5-IN-1 hydrochloride
PRMT5 IN-1 hydrochloride is a potent PRMT5 inhibitor (IC50: 11 nM), forms covalent adduct with C449, and converts to an aldehyde in vivo.Fórmula:C19H20Cl2N4O5Cor e Forma:SolidPeso molecular:455.29MC2652
<p>MC2652, a potent LSD1 inhibitor, suppresses leukemia (MV4-11, NB4) and impedes prostate cancer (LNCaP) cell growth.</p>Fórmula:C22H20N2OCor e Forma:SolidPeso molecular:328.41RU-0415529
CAS:RU-0415529 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (NSP14), with an IC50 of 356 nM. It inhibits viral RNA methylation and replication by stabilizing the cap-binding pocket through SAH binding. Additionally, RU-0415529 exhibits anti-infective activity in mouse models.Fórmula:C21H29N3O4SCor e Forma:SolidPeso molecular:419.538PKCiota-IN-1
CAS:<p>PKCiota-IN-1: Strong PKC-ι inhibitor (IC50=2.7 nM); also blocks PKC-α/ε (IC50s=45/450 nM).</p>Fórmula:C25H22FN5OCor e Forma:SolidPeso molecular:427.47L-Moses dihydrochloride
<p>L-Moses (L-45) dihydrochloride is the first, potent, selective p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor (Kd: 126 nM).</p>Fórmula:C21H26Cl2N6Cor e Forma:SolidPeso molecular:433.38WDR5-IN-5
CAS:WDR5-IN-5: Selective oral inhibitor for WDR5's WIN site with high affinity (Ki<0.02 nM) and anti-cancer properties. Good pharmacokinetics.Fórmula:C29H29F3N6OCor e Forma:SolidPeso molecular:534.58Menin-MLL inhibitor 26
CAS:Menin-MLL inhibitor 26: Active reference, inhibits cell growth, used in leukemia research.Fórmula:C27H29F3N6O3SCor e Forma:SolidPeso molecular:574.62Azaphilone-9
CAS:<p>AZA-9 inhibits cancer growth by blocking HuR-ARE RNA binding; IC50=1.2μM.</p>Fórmula:C21H23BrO5Cor e Forma:SolidPeso molecular:435.31JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Cor e Forma:SolidPF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Fórmula:C31H31FN8O2Pureza:98%Cor e Forma:SolidPeso molecular:566.63(2S,3R)-LP99
CAS:(2S,3R)-LP99 is a less active enantiomer of LP99.Fórmula:C26H30ClN3O4SPureza:98%Cor e Forma:SolidPeso molecular:516.05BET-IN-6
CAS:<p>BET-IN-6: Potent BRD2/4 inhibitor and ligand for PROTAC BRD2/BRD4 degrader-1 synthesis.</p>Fórmula:C22H20N2O6SPureza:98%Cor e Forma:SolidPeso molecular:440.47HDAC3-IN-3
CAS:<p>HDAC3-IN-3 (compound 31), a potent inhibitor of HDAC3, holds potential for cancer research [1].</p>Fórmula:C26H22N4O2Cor e Forma:SolidPeso molecular:422.48PARP1-IN-5
<p>PARP1-IN-5 is a potent, selective, orally active, low-toxicity PARP-1 inhibitor with an IC50 value of 14.7 nM. PARP1-IN-5 can be used in cancer research.</p>Fórmula:C25H24N2O5SCor e Forma:SolidPeso molecular:464.53HIF-2α-IN-7
CAS:<p>HIF-2α-IN-7 is a hypoxia inducible factor 2α (HIF-2α) inhibitor.</p>Fórmula:C18H9F6NO2Cor e Forma:SolidPeso molecular:385.26Aurora A inhibitor 1
CAS:Aurora A inhibitor 1: potent, selective, targets cancer-linked Aurora A overexpression, potential for cancer research. (WO2021147974A1, 49)Fórmula:C25H28ClF2N5O2Cor e Forma:SolidPeso molecular:503.97HDAC6-IN-12
HDAC6-IN-12 is a potent inhibitor of HDAC6 that binds in the DNA chain, causing DNA damage and exhibiting anticancer effects that can be used in cancer researchFórmula:C24H39F2N3O5Cor e Forma:SolidPeso molecular:487.58Basroparib
CAS:<p>Basroparib is an inhibitor of ribose polymerase (PARP) and has shown antitumour effects.</p>Fórmula:C18H21F2N7O3Cor e Forma:SolidPeso molecular:421.4MTL-CEBPA
MTL-CEPBA is a small activating RNA that targets C/EBPα upregulation and exhibits anti-inflammatory and anti-cancer effects.Cor e Forma:SolidAurora inhibitor 1
CAS:<p>Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).</p>Fórmula:C23H25N9SPureza:98%Cor e Forma:SolidPeso molecular:459.57MDH1/2-IN-1
CAS:<p>MDH1/2-IN-1 is an MDH1/2 inhibitor with IC50 values of 1.07 nM and 1.06 nM, respectively. It suppresses mitochondrial respiration and the HIF-1α pathway. MDH1/2-IN-1 exhibits significant antitumor potential and offers new avenues for developing drugs targeting cancer metabolism.</p>Fórmula:C25H33NO4Cor e Forma:SolidPeso molecular:411.534EED ligand 1
<p>EED ligand 1: potent PRC2 inhibitor targeting EED subunit.</p>Fórmula:C19H19FN8OCor e Forma:SolidPeso molecular:394.41WW437
WW437 is a histone deacetylase (HDAC) inhibitor that exhibits potent anti-breast cancer activity both in vitro and in vivo.Fórmula:C23H27N5O4Cor e Forma:SolidPeso molecular:437.49P300 bromodomain-IN-1
P300 bromodomain-IN-1 blocks c-Myc, induces G1/G0 arrest, apoptosis. Potent EP300 inhibitor (IC50: 49 nM).Fórmula:C29H31ClN4O4Cor e Forma:SolidPeso molecular:535.03BRD4-IN-7
CAS:<p>BRD4-IN-7, also known as compound 120, acts as a BRD4 inhibitor.</p>Fórmula:C29H24F2N4O3Cor e Forma:SolidPeso molecular:514.52JAK3-IN-11
CAS:JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.Fórmula:C23H23N5O2Cor e Forma:SolidPeso molecular:401.46GNE-886
CAS:<p>GNE-886 has a wide range of applications in life science related research.</p>Fórmula:C28H30N6O3Pureza:98%Cor e Forma:SolidPeso molecular:498.59PRMT5-IN-50
CAS:<p>PRMT5-IN-50 is an orally active selective inhibitor of PRMT5, demonstrating good metabolic stability and low clearance in human liver microsomes. It inhibits SDMA/HCT116-MTAPdel and SDMA/HCT116-MTAPwt with IC50 values for symmetric arginine methylation inhibition at 1.0 and 536 nM, respectively, and antiproliferative IC50 values at 19 and 1620 nM, respectively. Additionally, PRMT5-IN-50 suppresses tumor growth in mice.</p>Fórmula:C26H23F3N6OCor e Forma:SolidPeso molecular:492.496PARP7-IN-23
CAS:<p>PARP7-IN-23 (compound 56) is a potent PARP7 inhibitor with an EC50 of 0.915 nM for pSTAT1 in NCI-H1373 cells, indicating its potential for cancer research.</p>Fórmula:C27H22F7N5O3Cor e Forma:SolidPeso molecular:597.484FNDR-20123
FNDR-20123: First safe, effective anti-malarial HDAC inhibitor for Plasmodium (IC50: 31 nM) & human HDACs, with nanomolar potency across several subtypes.Fórmula:C21H24ClN5O2Cor e Forma:SolidPeso molecular:413.9WIZ degrader 8
CAS:<p>WIZ degrader 8 (compound 10) is a potent and selective molecular glue degrader of the transcription factor WIZ, effectively inducing HbF expression. It promotes WIZ degradation and HbF induction, suggesting its potential use as an inhibitor for sickle cell disease.</p>Fórmula:C21H27N3O4Cor e Forma:SolidPeso molecular:385.457MAT2A-IN-19
CAS:<p>MAT2A-IN-19 (Compound I-3) is an inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 32.93 nM.</p>Fórmula:C23H15F5N6O3Cor e Forma:SolidPeso molecular:518.396MAT2A-IN-16
CAS:<p>MAT2A-IN-16 is a MAT2A inhibitor that effectively suppresses the proliferation of MTAP-/-HCT-116 cells, with an IC50 value of 20 nM.</p>Fórmula:C23H17ClN6OCor e Forma:SolidPeso molecular:428.874MAT2A-IN-18
CAS:<p>MAT2A-IN-18 (Compound 15) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of 50 nM or less.</p>Fórmula:C17H13ClN4OCor e Forma:SolidPeso molecular:324.764O6BTG-C8-αGlu
CAS:<p>O6BTG-C8-αGlu is an O6-methylguanine-DNA methyltransferase (MGMT) inhibitor with an IC50 of 0.45 μM. At a concentration of 0.1 μM, it fully inhibits MGMT in HeLaS3 cells and demonstrates no cytotoxicity even at prolonged high doses (up to 20 μM). This compound is suitable for research on MGMT-related cancers.</p>Fórmula:C24H34BrN5O7SCor e Forma:SolidPeso molecular:616.525Balomenib
CAS:Balomenib is an inhibitor of the menin-MLL interaction, effectively blocking the men1-MLL4-43 interaction with an IC50 of less than 0.075 μM. It inhibits cell growth in MV4-11 (CC50 < 0.1 μM), MOLM-13 (CC50 0.1~0.5 μM), and HEK293 (CC50 < 2 μM) cells. Balomenib also exhibits antitumor activity.Fórmula:C33H34F3N7O2Cor e Forma:SolidPeso molecular:617.6646K465
CAS:6K465 is a potent Aurora A kinase inhibitor that reduces c-MYC and N-MYC oncoproteins, showing antiproliferative effects in SCLC and breast cancer cell lines.Fórmula:C26H33ClFN9OPureza:99.78%Cor e Forma:SolidPeso molecular:542.05JPHM-2-167
CAS:<p>PHM-2-167 (Compound 11) is a selective inhibitor of the prolyl hydroxylase domain enzyme (PHD). It inhibits PHD2 and PHD3 with IC50 values of 0.253 μM and 3.95 μM, respectively. PHM-2-167 is applicable for research in chronic kidney disease.</p>Fórmula:C30H28N6O2Cor e Forma:SolidPeso molecular:504.582BRD4 Inhibitor-33
CAS:<p>BRD4 Inhibitor-33 (example 13), a potent inhibitor of BRD4, is applicable in research related to both acute and chronic kidney diseases [1].</p>Fórmula:C24H20N4O2Cor e Forma:SolidPeso molecular:396.44MAT2A-IN-21
CAS:<p>MAT2A-IN-21 (compound 28) is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 49 nM. It selectively inhibits cancer cells with MTAP deficiency.</p>Fórmula:C26H20F2N4O2Cor e Forma:SolidPeso molecular:458.459PRMT5-IN-49
CAS:<p>PRMT5-IN-49 (Compound 4b16) is an inhibitor of PRMT5.</p>Fórmula:C19H22N2O2Cor e Forma:SolidPeso molecular:310.39W4275
CAS:<p>W4275 (Compound 42) is a selective NSD2 inhibitor with oral activity and an IC50 of 17 nM. It exhibits antiproliferative activity, with an IC50 of 230 nM against RS411 cells, and significantly inhibits tumor growth in an RS411 tumor xenograft model. Pharmacokinetic analysis in mice shows that W4275 has a favorable oral bioavailability (F is 27.34%). W4275 holds potential for use in cancer research.</p>Fórmula:C25H36N6O3Cor e Forma:SolidPeso molecular:468.59NSD2-PWWP1-IN-1
CAS:<p>NSD2-PWWP1-IN-1 (compound 31) is a potent inhibitor of NSD2-PWWP1 with an IC50 value of 0.64 µM, demonstrating potential applications in cancer research.</p>Fórmula:C28H30N4Cor e Forma:SolidPeso molecular:422.565IBL-302
CAS:IBL-302 (AMU302), an orally available dual-signaling inhibitor targeting PIM and PI3K/AKT/mTOR, is effective against breast cancer and neuroblastoma. It has shown in vivo efficacy in a nude mouse xenograft model by combating trastuzumab resistance. Additionally, IBL-302 augments the effectiveness of widely used cytotoxic chemotherapy drugs such as cisplatin, doxorubicin, and etoposide [1] [2] [3].Fórmula:C25H18FN5O4S3Cor e Forma:SolidPeso molecular:567.64SE-7552
CAS:<p>SE-7552, a derivative of 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO), serves as an orally active, highly selective non-hydroxamate HDAC6 inhibitor, boasting an IC50 of 33 nM. It exhibits over 850-fold selectivity against all other known HDAC isozymes. Demonstrating efficacy in vivo, SE-7552 effectively inhibits the growth of multiple myeloma. Additionally, it functions as an anti-obesity agent in diet-induced obese mice [1] [2].</p>Fórmula:C15H12F3N5OCor e Forma:SolidPeso molecular:335.28JAK1/TYK2-IN-4
CAS:<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Fórmula:C17H23N7OCor e Forma:SolidPeso molecular:341.41GSK8814
CAS:GSK8814 is a selective and ATAD2/2B bromodomain chemical probe and inhibitor (binding constant pKd=8.1 and a pKi=8.9 in BROMOscan).Fórmula:C28H35F2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:527.61INCB054329
CAS:INCB054329 is a BET inhibitor targeting BRD2/3/4 and BRDT with IC50s ranging from 1-119 nM.Fórmula:C19H16N4O3Pureza:99.52%Cor e Forma:SolidPeso molecular:348.36ORIC-944
CAS:<p>ORIC-944 is an orally available, selective variant of PRC2 with anticancer activity for the study of prostate cancer.</p>Fórmula:C26H25FN6OPureza:98.08%Cor e Forma:SolidPeso molecular:456.52BAY-3827
CAS:BAY-3827 is an AMPK inhibitor with antiproliferative activity and antitumor activity. BAY-3827 inhibits the phosphorylation of acetyl CoA carboxylase 1.Fórmula:C27H25FN6OPureza:99.90%Cor e Forma:SolidPeso molecular:468.53AMG-193
CAS:AMG-193 is an inhibitor of the MTA-PRMT5 complex and is used in the study of cancer, respiratory diseases and digestive disorders.Fórmula:C22H19F3N4O3Pureza:99.52%Cor e Forma:SolidPeso molecular:444.41EZM0414
CAS:EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 with IC50 of 18 nM in SETD2 biochemical assay and IC50 of 34 nM in a cellular assay.Fórmula:C22H29FN4O2Pureza:99.58%Cor e Forma:SolidPeso molecular:400.49YTH-IN-1
CAS:YTH-IN-1 is an inhibitor of the five YTH structural domains in the human.The YTH family of proteins is an N 6-methyladenosine (m6A) reader in gene expression.Fórmula:C18H24N6O3Pureza:98.46% - 99.94%Cor e Forma:SolidPeso molecular:372.42Pocenbrodib
CAS:<p>Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.</p>Fórmula:C28H32FN3O6Pureza:98.48% - 99.54%Cor e Forma:SolidPeso molecular:525.57GSK3368715 dihydrochloride
CAS:GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is a PRMTs inhibitor , with anticancer activity, for the study of advanced solid tumors.Fórmula:C20H40Cl2N4O2Pureza:99.66% - 99.66%Cor e Forma:SolidPeso molecular:439.46LLY-283
CAS:LLY-283, PRMT5 inhibitor, IC50 22 nM, Kd 6 nM, oral, selective, with antitumor effects.Fórmula:C17H18N4O4Pureza:99.49%Cor e Forma:SolidPeso molecular:342.35DN02
<p>DN02: a potent, selective BRD8(1) bromodomain probe; Ki=32 nM; 30x more affine than BRD8(2).</p>Fórmula:C22H24FN3O3Pureza:98.22% - 99.74%Cor e Forma:SolidPeso molecular:397.44JDTic
CAS:JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Fórmula:C28H39N3O3Cor e Forma:SolidPeso molecular:465.63Sinefungin
CAS:Sinefungin (Adenosyl-Ornithine) is an effective inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viralFórmula:C15H23N7O5Pureza:98.12%Cor e Forma:SolidPeso molecular:381.39BRD0639
CAS:<p>BRD0639 is a first-in-class PRMT5-substrate interaction inhibitor for PBM-dependent PRMT5 activity studies.</p>Fórmula:C21H22ClN5O4SPureza:99.85%Cor e Forma:SolidPeso molecular:475.95(8R,9S)-Talazoparib
CAS:(8R,9S)-Talazoparib is Talazoparib enantiomer , less active than Talazoparib on the inhibition of PARP1 (IC50: 144 nM).Fórmula:C19H14F2N6OCor e Forma:SolidPeso molecular:380.35EHMT2-IN-2
CAS:EHMT2-IN-2 Used in the research of blood disease or cancer. EHMT2-IN-2 is a potent EHMT inhibitor, with IC50s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2.Fórmula:C21H22N6OCor e Forma:SolidPeso molecular:374.44Amredobresib
CAS:Amredobresib is a potent BET inhibitor that impedes the interaction between bromodomains and acetylated lysines on histone H3 and H4, thereby serving as crucial regulators of gene transcription. It proves valuable in the investigation of acute myeloid leukemia (AML) and cancer.Fórmula:C26H29N9Cor e Forma:SolidPeso molecular:467.581Cercosporin
CAS:<p>Cercosporin, produced by the plant pathogen Cercospora kikuchii and the elsinochromes, is a potent photosensitizer with a short activation wavelength. Cercosporin contains perylene quinone structural features essential for PKC activity (IC50: 0.6-1.3 μM).</p>Fórmula:C29H26O10Pureza:98%Cor e Forma:SolidPeso molecular:534.51BD-9136
<p>BD-9136, a highly selective BRD4 degrader, demonstrates the capability to inhibit tumor growth without inducing adverse effects in mice, showing potential for</p>Fórmula:C44H44N10O5SPureza:98%Cor e Forma:SolidPeso molecular:824.95(3R,4S)-Tofacitinib
CAS:(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Fórmula:C16H20N6OPureza:98%Cor e Forma:SolidPeso molecular:312.37HIF-PHD-IN-1
CAS:<p>HIF-PHD-IN-1 is a pharmacological compound that acts as an orally active inhibitor of the hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD), displaying an IC50 of 54 nM for hHIF-PHD2. Its potential as a therapeutic agent for renal anemia is highly promising.</p>Fórmula:C17H12Cl2N6O3Cor e Forma:SolidPeso molecular:419.22CARM1-IN-1 hydrochloride
CAS:CARM1-IN-1 hydrochloride is a potent and selective inhibitor of CARM1 (IC50: 8.6 μM) with minimal inhibition of PRMT1 and SET7.Fórmula:C26H22Br2ClNO3Cor e Forma:SolidPeso molecular:591.72HJB97
CAS:HJB97 is used for the design of potential PROTAC BET degrader. It also has antitumor activity. HJB97 is a high-affinity inhibitor of BET (Kis: 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2), 0.18 nM (BRD3 BD1), 0.21 nM (BRD3 BD2), 0.5 nM (BRD4 BD1), 1.0 nM (BRD4 BD2), respectively).Fórmula:C26H28N8O3Pureza:98%Cor e Forma:SolidPeso molecular:500.55Ref: TM-T15484
Produto descontinuadoYF-2 hydrochloride
CAS:<p>YF-2 hydrochloride is a potent histone acetyltransferase activator that exhibits high selectivity and can pass through the blood-brain barrier. It specifically acetylates H3 in the hippocampus, with EC50 values of 2.75 μM, 29.04 μM, and 49.31 μM for CBP, PCAF, and GCN5, respectively. Notably, it does not affect HDAC activity. Moreover, YF-2 hydrochloride demonstrates promising anti-cancer and anti-Alzheimer's disease properties.</p>Fórmula:C20H23Cl2F3N2O3Cor e Forma:SolidPeso molecular:467.31PLK1-IN-6
<p>PLK1-IN-6: potent, selective PLK1 inhibitor, IC50 = 0.45 nM, hinders cancer cell growth.</p>Fórmula:C28H37N9O3Cor e Forma:SolidPeso molecular:547.6520-HETE
CAS:<p>20-HETE is a CYP450 product, vasoconstrictor, modulates K+ channels, affects NADPH, ROS, NF-κB, NO synthase, and cell apoptosis/proliferation.</p>Fórmula:C20H32O3Pureza:99.79%Cor e Forma:SolidPeso molecular:320.47PARP1 Protein, Human, Recombinant (His)
<p>PARP Protein, Human, Recombinant (His) is expressed in Baculovirus insect cells with His tag.</p>Pureza:94.1%Cor e Forma:Lyophilized PowderPeso molecular:114.5 kDa (predicted); 100-110 kDa (reducing conditions)CTB
CAS:<p>CTB (Cholera Toxin B subunit) is an activator of p300 histone acetyltransferase and induces apoptosis in MCF-7 cells.</p>Fórmula:C16H13ClF3NO2Pureza:99.82%Cor e Forma:SolidPeso molecular:343.73Desidustat
CAS:<p>Desidustat is an inhibitor of HIF hydroxylase.</p>Fórmula:C16H16N2O6Pureza:98%Cor e Forma:SolidPeso molecular:332.31BLL5 Maleate
CAS:<p>BLL5 Maleate is a first-in-class selective PRMT5 inhibitor, it blocks EBV-driven B lymphocyte transformation and survival while leaving normal B cells unaffected.</p>Fórmula:C21H21N3Pureza:98%Cor e Forma:SolidPeso molecular:315.41BET-IN-15
CAS:<p>BET-IN-15 (compound 1) is a potent, orally active inhibitor of BET, demonstrating inhibitory IC50 values of 0.64 nM for BRD4-BD1 and 0.25 nM for BRD4-BD2.</p>Fórmula:C21H18F2N4O3SPureza:98%Cor e Forma:SolidPeso molecular:444.45Ref: TM-T79167
Produto descontinuadoBisindolylmaleimide I HCl
CAS:Bisindolylmaleimide I HCl is a specific ATP-competitive PKC inhibitor.Fórmula:C25H25ClN4O2Pureza:98%Cor e Forma:SolidPeso molecular:448.95AMPK activator C2
CAS:AMPK activator C2 is an AMPK allosteric activator.Fórmula:C7H6NO6PPureza:98%Cor e Forma:SolidPeso molecular:231.1JAK2-IN-9
CAS:<p>Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.</p>Fórmula:C20H24N6O2SPureza:98%Cor e Forma:SolidPeso molecular:412.51Ref: TM-T79581
Produto descontinuadoLerzeparib
CAS:<p>Lerzeparib is a PARP (ADP-ribose polymerase) inhibitor that exhibits antineoplastic activity [1].</p>Fórmula:C21H20FN3O2Pureza:98%Cor e Forma:SolidPeso molecular:365.4JAK-IN-34
CAS:<p>JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,</p>Fórmula:C27H26N6OPureza:98%Cor e Forma:SolidPeso molecular:450.53Antitumor agent-104
CAS:<p>Antitumor Agent-104 (Compound 9) serves as an antineoplastic by impeding DNA repair mechanisms in tumor cells, primarily through the inhibition of PARP1 enzyme</p>Fórmula:C31H33FN6O3Pureza:98%Cor e Forma:SolidPeso molecular:556.63JAK1-IN-10
CAS:<p>JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].</p>Fórmula:C15H17N7Pureza:98%Cor e Forma:SolidPeso molecular:295.34JAK1-IN-11
CAS:<p>JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.</p>Fórmula:C26H36N6O4SPureza:98%Cor e Forma:SolidPeso molecular:528.67BBDDL2059
CAS:<p>BBDDL2059 is a selective covalent inhibitor targeting EZH2, exhibiting an IC50 of 1.5 nM against the EZH2-Y641F mutant.</p>Fórmula:C27H36N4O4SPureza:98%Cor e Forma:SolidPeso molecular:512.66Ref: TM-T79200
Produto descontinuadoBAZ2-ICR
CAS:<p>BAZ2-ICR is an epigenetic chemical probe and it also is a potent, selective, cell active and orally active BAZ2A/B bromodomains inhibitor with IC50s of 130 nM and 180 nM, and Kds of 109 nM and 170 nM, respectively. BAZ2-ICR shows 10-15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains.</p>Fórmula:C20H19N7Pureza:98%Cor e Forma:SolidPeso molecular:357.41DPP
CAS:<p>DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating</p>Fórmula:C36H40Cl2N2O10PtPureza:98%Cor e Forma:SolidPeso molecular:926.7STAT3-IN-18
CAS:<p>STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and</p>Fórmula:C18H24Cl2N2O6PtPureza:98%Cor e Forma:SolidPeso molecular:630.38BET-IN-14
CAS:<p>BET-IN-14 is a pan BET inhibitor with an IC50 of 5.35 nM, demonstrating oral activity and anticancer properties [1].</p>Fórmula:C30H37N7O2Pureza:98%Cor e Forma:SolidPeso molecular:527.66Igermetostat
CAS:<p>Igermetostat, an EZH2 inhibitor, is utilized both in vivo and in vitro for cancer research [1].</p>Fórmula:C32H46N4O4Pureza:98%Cor e Forma:SolidPeso molecular:550.73JAK-IN-27
CAS:<p>JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM</p>Fórmula:C20H21F2N7OPureza:98%Cor e Forma:SolidPeso molecular:413.42BET BD2-IN-3
CAS:<p>BET BD2-IN-3 (compound I-58), a BET inhibitor specifically targeting the BD2 domain, can be radiolabeled with [11C] for use in positron emission tomography (PET) imaging. PET studies with [11C]BD2-IN-3 in mice have demonstrated appropriate biodistribution in peripheral organs and tissues.</p>Fórmula:C29H30N4OCor e Forma:SolidPeso molecular:450.58PARP7-IN-16 free base
CAS:<p>PARP7-IN-16 free base is the freebase form of PARP7-IN-16. As a selective oral inhibitor of PARP-1/2/7, it demonstrates IC50 values of 0.94, 0.87, and 0.21 nM, respectively. This compound is utilized in the research of breast and prostate cancer.</p>Fórmula:C25H27FN4O4Cor e Forma:SolidPeso molecular:466.50Ref: TM-T200703
Produto descontinuadoBB-Cl-Amidine hydrochloride
CAS:BB-Cl-Amidine hydrochloride is an inhibitor of peptidylarginine deminase (PAD) [1].Fórmula:C26H27Cl2N5OPureza:98%Cor e Forma:SolidPeso molecular:496.43
